AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program | AIM Stock NewsStockTitan·Jul 7 at 12:03 AMAIM-0.40%AZN+0.59%
AIM ImmunoTech completes Phase 2 DURIPANC trial enrollment for Ampligen-Imfinzi in metastatic pancreatic cancerPUBT·Jun 24 at 07:29 AMAZN+0.59%AIM-0.40%
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar SeriesUnusual Whales·Jun 22 at 07:47 AMAIM-0.40%BULL-4.46%
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer | AIM Stock NewsStockTitan·Jun 18 at 12:01 AMAIM-0.40%AZN+0.59%
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga_article·Jun 12 at 12:05 PMCUPR+0.76%AIM-0.40%
AIM ImmunoTech Prices $1.3 Million Registered Direct Offering; Adds $5.3 Million Warrant UpsideTradingView·Jun 11 at 03:23 PMAIM-0.40%
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga_article·Jun 9 at 12:06 PMALHC-2.85%NUVL0.00%
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules | AIM Stock NewsStockTitan·Jun 9 at 12:29 AMAIM-0.40%
